Palliative bypass surgery for patients with advanced pancreatic adenocarcinoma: experience from a tertiary center.
Aged
Aged, 80 and over
Carcinoma, Pancreatic Ductal
/ pathology
Female
Gastric Bypass
/ adverse effects
Humans
Male
Middle Aged
Palliative Care
Pancreatic Neoplasms
/ pathology
Postoperative Complications
/ etiology
Retrospective Studies
Risk Factors
Survival Analysis
Tertiary Care Centers
Treatment Outcome
Bypass surgery
Gastrojejunostomy
Hepaticojejunostomy
Palliation
Journal
World journal of surgical oncology
ISSN: 1477-7819
Titre abrégé: World J Surg Oncol
Pays: England
ID NLM: 101170544
Informations de publication
Date de publication:
01 Apr 2020
01 Apr 2020
Historique:
received:
27
01
2020
accepted:
25
02
2020
entrez:
3
4
2020
pubmed:
3
4
2020
medline:
16
12
2020
Statut:
epublish
Résumé
As advances in oncological treatment continue to prolong the survival of patients with non-resectable pancreatic ductal adenocarcinoma (PDAC), decision-making regarding palliative surgical bypass in patients with a heavy disease burden turns challenging. Here we present the results of a pancreatic surgery referral center. Patients that underwent palliative gastrojejunostomy and/or hepaticojejunostomy for advanced, non-resectable PDAC between January 2010 and November 2018 were retrospectively assessed. All patients were taken to a purely palliative surgery with no curative intent. The postoperative course as well as short and long-term outcomes was evaluated in relation to preoperative parameters. Forty-two patients (19 females) underwent palliative bypass. Thirty-one underwent only gastrojejunostomy (22 laparoscopic) and 11 underwent both gastrojejunostomy and hepaticojejunostomy (all by an open approach). Although 34 patients (80.9%) were able to return temporarily to oral intake during the index admission, 15 (35.7%) suffered from a major postoperative complication. Seven patients (16.6%) died from surgery and another seven within the following month. Nine patients (21.4%) never left the hospital following the surgery. Mean length of hospital stay was 18 ± 17 days (range 3-88 days). Mean overall survival was 172.8 ± 179.2 and median survival was 94.5 days. Age, preoperative hypoalbuminemia, sarcopenia, and disseminated disease were associated with palliation failure, defined as inability to regain oral intake, leave the hospital, or early mortality. Although palliative gastrojejunostomy and hepaticojejunostomy may be beneficial for specific patients, severe postoperative morbidity and high mortality rates are still common. Patient selection remains crucial for achieving acceptable outcomes.
Sections du résumé
BACKGROUND
BACKGROUND
As advances in oncological treatment continue to prolong the survival of patients with non-resectable pancreatic ductal adenocarcinoma (PDAC), decision-making regarding palliative surgical bypass in patients with a heavy disease burden turns challenging. Here we present the results of a pancreatic surgery referral center.
METHODS
METHODS
Patients that underwent palliative gastrojejunostomy and/or hepaticojejunostomy for advanced, non-resectable PDAC between January 2010 and November 2018 were retrospectively assessed. All patients were taken to a purely palliative surgery with no curative intent. The postoperative course as well as short and long-term outcomes was evaluated in relation to preoperative parameters.
RESULTS
RESULTS
Forty-two patients (19 females) underwent palliative bypass. Thirty-one underwent only gastrojejunostomy (22 laparoscopic) and 11 underwent both gastrojejunostomy and hepaticojejunostomy (all by an open approach). Although 34 patients (80.9%) were able to return temporarily to oral intake during the index admission, 15 (35.7%) suffered from a major postoperative complication. Seven patients (16.6%) died from surgery and another seven within the following month. Nine patients (21.4%) never left the hospital following the surgery. Mean length of hospital stay was 18 ± 17 days (range 3-88 days). Mean overall survival was 172.8 ± 179.2 and median survival was 94.5 days. Age, preoperative hypoalbuminemia, sarcopenia, and disseminated disease were associated with palliation failure, defined as inability to regain oral intake, leave the hospital, or early mortality.
CONCLUSIONS
CONCLUSIONS
Although palliative gastrojejunostomy and hepaticojejunostomy may be beneficial for specific patients, severe postoperative morbidity and high mortality rates are still common. Patient selection remains crucial for achieving acceptable outcomes.
Identifiants
pubmed: 32238149
doi: 10.1186/s12957-020-01828-5
pii: 10.1186/s12957-020-01828-5
pmc: PMC7114792
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
63Références
Cancers (Basel). 2019 May 13;11(5):
pubmed: 31086093
Arch Surg. 2011 May;146(5):517-22
pubmed: 21576604
World J Surg Oncol. 2019 Jan 31;17(1):26
pubmed: 30704497
N Engl J Med. 2011 May 12;364(19):1817-25
pubmed: 21561347
Ann Surg Oncol. 2003 Jul;10(6):654-63
pubmed: 12839850
Ann Surg. 2003 Dec;238(6):894-902; discussion 902-5
pubmed: 14631226
Cancer Treat Rev. 2019 Jul;77:1-10
pubmed: 31163334
N Engl J Med. 2010 Apr 29;362(17):1605-17
pubmed: 20427809
World J Gastrointest Surg. 2018 Oct 27;10(7):75-83
pubmed: 30397425
J Gastrointest Surg. 2011 Nov;15(11):1917-27
pubmed: 21913044
J Surg Oncol. 2014 Jun;109(7):697-701
pubmed: 24395080
J Gastrointest Surg. 2014 Jul;18(7):1292-8
pubmed: 24671470
Ann Surg. 2013 Jan;257(1):17-26
pubmed: 22895395
Dig Dis Sci. 2014 Sep;59(9):2294-8
pubmed: 24781163
J Clin Gastroenterol. 2008 Jan;42(1):86-91
pubmed: 18097296
Age Ageing. 2019 Jan 1;48(1):16-31
pubmed: 30312372
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Ann Surg. 2004 Oct;240(4):719-26; discussion 726-7
pubmed: 15383799
Ann Surg. 2009 Aug;250(2):187-96
pubmed: 19638912
Pancreas. 2010 Nov;39(8):1247-53
pubmed: 20683218